[[(3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]amino] N-phenylcarbamate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [[(3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]amino] N-phenylcarbamate
• 化学式: C₁₅H₂₁N₃O₇
• 分子量: 355.34
• InChiKey: BBEBTBDOQNIYPZ-GNMOMJPPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  149
• 氢给体数：
  6
• 氢受体数：
  8

文献信息

• [EN] SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS SÉLECTIFS DE GLYCOSIDASES ET LEURS UTILISATIONS
  申请人：ALECTOS THERAPEUTICS INC

  公开号：WO2012129651A1

  公开（公告）日：2012-10-04

  The invention provides compounds of formula (I) with substituents as specified in claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to over-expression of O-GlcNAcase or accumulation of O-GlcNac.

  该发明提供了具有特定取代基的化合物（I）的公式，用于选择性抑制糖苷酶，该化合物的前药，以及包括该化合物或其前药的药物组合物。该发明还提供了治疗与O-GlcNAcase过度表达或O-GlcNac积累相关的疾病和疾病的方法。
• IMMUNOGENIC VACCINE
  申请人：University of Georgia Research Foundation, Inc.

  公开号：US20150299290A1

  公开（公告）日：2015-10-22

  A glycolipopeptide comprising a carbohydrate component, a lipid component, and a MUC1 peptide component that induces both a humoral and a cellular immune response for use as a therapeutic or prophylactic vaccine.

  一种含有碳水化合物组分、脂质组分和MUC1肽组分的糖脂肽，可诱导细胞免疫和体液免疫反应，用作治疗或预防性疫苗。
• SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
  申请人：Alectos Therapeutics Inc.

  公开号：EP2691407A1

  公开（公告）日：2014-02-05
• Compositions and Methods for Improving Heart Function
  申请人：Dillmann Wolfgang

  公开号：US20080313753A1

  公开（公告）日：2008-12-18

  The present invention relates to treating or ameliorating heart disease associated with poor myocardial performance, e.g., diabetic cardiomyopathy and associated disorders, particularly to treating, preventing or ameliorating such disorders through inhibition of O-GlcNAcylation and/or increased activity of O-GlnNAcase. The invention provides vectors for gene transfer of O-GlnNAcase. In one aspect, the invention provides cells, vectors, formulations comprising them and methods of using them, for the gene transfer of the human O-GlnNAcase gene, e.g., to treat conditions and diseases associated with impaired cardiac contractility, such as that, found associated with diabetic cardiomyopathy. In another aspect, the invention provides non-human transgenic animals and host cells comprising genetically engineered cells having increased activity of O-GlnNAcase.
• GLYCOPEPTIDE AND USES THEREOF
  申请人：Boons Geert-Jan

  公开号：US20120039984A1

  公开（公告）日：2012-02-16

  A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.